We have previously identified thymocyte selection-associated high mobility group (HMG) box protein (TOX) as a promising drug target in CTCL; however, there are currently no small molecules able to directly inhibit TOX. The gene discussed is TOX; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.